111 Inc

111 Inc(YI)股票分析

$2.900

-0.078 (-2.68%)收盤時

Loading chart…
最高
2.950
開盤
2.950
成交量加權均價
2.92
成交量
56.91K
市值
92.95M
最低
2.900
成交金額
165.98K
企業價值/稅息折舊攤銷前利潤(TTM)
0.08

111 Inc is an investment holding company primarily engaged in the operation of integrated online and offline healthcare platform. The Company mainly operates its business through two segments. The Business to Customer (B2C) segment is engaged in the sale of pharmaceutical and other health and wellness products through 1 Medicine Marketplace, mobile apps, other online channels and offline pharmacies to consumers and certain enterprise customers. The Business to Business (B2B) segment is engaged in the sale of pharmaceutical products to pharmacies on 1 Pharmacy. The Company also provides customers with online consultation and electronic prescription services through the Internet hospital 1 Clinic. The Company’s products include drugs, nutritional supplements, medical supplies and devices and other products. The Company mainly conducts its business in the domestic market.

AI 分析 of 111 Inc (YI)

持有

Currently, 111 Inc (YI) is not a strong buy due to its significant financial challenges. The stock is trading at $2.90, with a 52-week high of $11.17, indicating a potential for recovery, but the RSI is at 36.67, suggesting it is nearing oversold territory. However, the company reported a 33.1% year-over-year revenue decline in Q1 2026 and a net income of -$37.04 million in Q1 2026, which raises concerns about its profitability and future growth prospects. The main risk is the company's high debt-to-equity ratio of 1199.60%, indicating significant financial leverage and potential liquidity issues.

分析師評級(1)

買進
1 買進
0 持有
0 賣出
目前: 2.90
最低
—
平均
—
最高
—

估值指標

111 Inc(YI)目前預期本益比為 0.00,5 年平均預期本益比為 18.30。

預期本益比

合理
5 年均值 P/E
18.30
目前P/E
0.00
高估
68.20
低估
-31.60

預期 EV/EBITDA

合理
5 年均值 EV/EBITDA
3.81
目前EV/EBITDA
0.08
高估
27.87
低估
-20.26

預期股價營收比

嚴重低估
5 年均值 P/S
0.07
目前P/S
0.00
高估
0.09
低估
0.04

事件時間軸

2026-09-28 (ET)

06:30:00

111, Inc. Establishes Special Committee to Evaluate Strategic Proposals

2026-09-17 (ET)

05:30:00

111 Inc. Receives Acquisition Proposal at $0.226 per Share

2026-01-30 (ET)

14:50:00

111 Inc ADR Trading Halted Due to Volatility Trading Pause

2025-02-11 (ET)

07:01:56

111, Inc. regains Nasdaq compliance

2025-01-08 (ET)

04:08:32

111, Inc. announces one-for-twenty ADS ratio change

資訊

YI 常見問題 —— 由 Alphio AI 解答

111 Inc is an investment holding company primarily engaged in the operation of integrated online and offline healthcare platform. The Company mainly operates its business through two segments. The Business to Customer (B2C) segment is engaged in the sale of pharmaceutical and other health and wellness products through 1 Medicine Marketplace, mobile apps, other online channels and offline pharmacies to consumers and certain enterprise customers. The Business to Business (B2B) segment is engaged in the sale of pharmaceutical products to pharmacies on 1 Pharmacy. The Company also provides customers with online consultation and electronic prescription services through the Internet hospital 1 Clinic. The Company’s products include drugs, nutritional supplements, medical supplies and devices and other products. The Company mainly conducts its business in the domestic market. It operates in the Healthcare sector (DRUG STORES AND PROPRIETARY STORES industry).

Currently, 111 Inc (YI) is not a strong buy due to its significant financial challenges. The stock is trading at $2.90, with a 52-week high of $11.17, indicating a potential for recovery, but the RSI is at 36.67, suggesting it is nearing oversold territory. However, the company reported a 33.1% year-over-year revenue decline in Q1 2026 and a net income of -$37.04 million in Q1 2026, which raises concerns about its profitability and future growth prospects. The main risk is the company's high debt-to-equity ratio of 1199.60%, indicating significant financial leverage and potential liquidity issues.

1 analysts cover YI: 1 rate it Buy, 0 Hold and 0 Sell.

暫無貼文

註冊或登入後參與討論

相關文章

本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。

開始交易